MARKET

VNRX

VNRX

VOLITIONRX
AMEX

Real-time Quotes | Nasdaq Last Sale

3.170
-0.020
-0.63%
Closed 16:00 09/16 EDT
OPEN
3.200
PREV CLOSE
3.190
HIGH
3.200
LOW
3.120
VOLUME
51.39K
TURNOVER
--
52 WEEK HIGH
6.67
52 WEEK LOW
2.850
MARKET CAP
168.47M
P/E (TTM)
-7.5101
1D
5D
1M
3M
1Y
5Y
Life Sciences Virtual Investor Conference: Company Executives Present Live September 16th
Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.comNEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private...
GlobeNewswire · 6d ago
VNRX: Revenues from Nu.Q Vet Cancer Screening Test steady from beta test; Silver One expected to generate revenues in late 2021.
By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT
Benzinga · 08/18 19:40
Sidoti Microcap Virtual Conference
ACCESSWIRE · 08/18 12:45
Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021
The SNN Network Summer Virtual Event will take place on August 17-19, 2021, where 60 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience.
ACCESSWIRE · 08/16 12:32
Diamond Equity Research Emerging Growth Invitational Summer 2021 Spotlight Virtual Conference
30 Minute presenting time slots from 9am to 12pm EST August 17th, 2021Presentation times and links distributed for all presenting companiesInvestors will be provided time after presentation to ask questions to management teamsWe welcome all institutional a...
GlobeNewswire · 08/12 13:00
BRIEF-VolitionRX Ltd Q2 Posts Net Loss Of $5.6 Million
reuters.com · 08/11 21:29
VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter ended June 30, 2021. Volition management will host a conference call tomorrow, August 12 at 8:00 a.m. U.S. Eastern Time to ...
PR Newswire · 08/11 20:10
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the...
Benzinga · 08/08 14:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VNRX. Analyze the recent business situations of VOLITIONRX through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VNRX stock price target is 8.00 with a high estimate of 10.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 24
Institutional Holdings: 3.02M
% Owned: 5.69%
Shares Outstanding: 53.15M
TypeInstitutionsShares
Increased
9
101.54K
New
1
802
Decreased
4
84.17K
Sold Out
2
35.57K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.13%
Healthcare Equipment & Supplies
-0.15%
Key Executives
Chairman/Executive Director
Martin Faulkes
Chief Executive Officer/President/Director
Cameron Reynolds
Chief Financial Officer/Treasurer
Terig Hughes
Corporate Executive
Salvatore Butera
Corporate Executive
Jasmine Kway
Chief Scientific Officer
Jacob Micallef
Other
Gael Forterre
Other
Jason Terrell
Secretary
Rodney Rootsaert
Independent Director
Phillip Barnes
Independent Director
Richard Brudnick
Independent Director
Alan Colman
Independent Director
Edward Futcher
Independent Director
Guy Innes
Independent Director
Kim Nguyen
No Data
  • All
  • Financials
  • Insiders
More
About VNRX
VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company's Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Company is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company's NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. It has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.

Webull offers kinds of VolitionRX Ltd stock information, including AMEX:VNRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VNRX stock methods without spending real money on the virtual paper trading platform.